Aurinia Pharmaceuticals (AUPH) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Aurinia Pharmaceuticals Inc. presented new data at ASN Kidney Week 2024, highlighting the effectiveness of LUPKYNIS in treating lupus nephritis, particularly in diverse populations most affected by the disease. Real-world data showcased LUPKYNIS’s positive impact on kidney health compared to older therapies, with studies indicating improved outcomes and stronger podocyte stability at lower doses.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
